Taflotan

What are the side effects you encounter while taking this medicine?  No   Yes

Taflotan uses

• Indications and usage
• Dosage and administration
• Dosage forms and strengths
• Contraindications
• Warnings and precautions
• Adverse reactions
• Use in specific populations
• Description
• Clinical pharmacology
• Nonclinical toxicology
• Clinical studies
• How supplied/storage and handling
• Patient counseling information
• Taflotan reviews

1 INDICATIONS AND USAGE

Taflotan^® (tafluprost ophthalmic solution) 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

• Taflotan ^® (tafluprost ophthalmic solution) 0.0015% is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. (1)

2 DOSAGE AND ADMINISTRATION

The recommended dose is one drop of Taflotan^® in the conjunctival sac of the affected eye(s) once daily in the evening.

The dose should not exceed once daily since it has been shown that more frequent administration of prostaglandin analogs may lessen the intraocular pressure lowering effect.

Reduction of the intraocular pressure starts approximately 2 to 4 hours after the first administration with the maximum effect reached after 12 hours.

Taflotan^® may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is being used, each one should be administered at least 5 minutes apart.

The solution from one individual unit is to be used immediately after opening for administration to one or both eyes. Since sterility cannot be maintained after the individual unit is opened, the remaining contents should be discarded immediately after administration.

• One drop in the affected eye(s) once daily in the evening. (2)

3 DOSAGE FORMS AND STRENGTHS

Ophthalmic solution containing Taflotan 0.015 mg/mL.

• Ophthalmic solution containing Taflotan 0.015 mg/mL. (3)

4 CONTRAINDICATIONS

None.

• None. (4)

5 WARNINGS AND PRECAUTIONS

• Pigmentation

Pigmentation of the iris, periorbital tissue and eyelashes can occur. Iris pigmentation is likely to be permanent. (5.1)

• Eyelash Changes

Gradual changes to eyelashes including increased length, thickness and number of lashes. Usually reversible. (5.2)

5.1 Pigmentation

Taflotan ophthalmic solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes. Pigmentation is expected to increase as long as Taflotan is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of Taflotan, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long term effects of increased pigmentation are not known.

Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with Taflotan^® can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly. .

5.2 Eyelash Changes

Taflotan^® may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, color, thickness, shape and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment.

5.3 Intraocular Inflammation

Taflotan^® should be used with caution in patients with active intraocular inflammation because the inflammation may be exacerbated.

5.4 Macular Edema

Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin F2α analogs. Taflotan^® should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

6 ADVERSE REACTIONS

• Most common ocular adverse reaction is conjunctival hyperemia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Akorn, Inc. at 1-800-932-5676 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Studies Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Preservative-containing or preservative-free Taflotan 0.0015% was evaluated in 905 patients in five controlled clinical studies of up to 24-months duration. The most common adverse reaction observed in patients treated with Taflotan was conjunctival hyperemia which was reported in a range of 4% to 20% of patients. Approximately 1% of patients discontinued therapy due to ocular adverse reactions.

Ocular adverse reactions reported at an incidence of ≥2% in these clinical studies included ocular stinging/irritation (7%), ocular pruritus including allergic conjunctivitis (5%), cataract (3%), dry eye (3%), ocular pain (3%), eyelash darkening (2%), growth of eyelashes (2%) and vision blurred (2%).

Nonocular adverse reactions reported at an incidence of 2% to 6% in these clinical studies in patients treated with Taflotan 0.0015% were headache (6%), common cold (4%), cough (3%) and urinary tract infection (2%).

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of Taflotan. Because postapproval adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Respiratory disorders: exacerbation of asthma, dyspnea

Eye disorders: iritis/uveitis

In postmarketing use with prostaglandin analogs, periorbital and lid changes including deepening of the eyelid sulcus have been observed.

8 USE IN SPECIFIC POPULATIONS

• Use in pediatric patients is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

8.1 Pregnancy

Pregnancy Category C.

Teratogenic effects: In embryo-fetal development studies in rats and rabbits, Taflotan administered intravenously was teratogenic. Taflotan caused increases in post-implantation losses in rats and rabbits and reductions in fetal body weights in rats. Taflotan also increased the incidence of vertebral skeletal abnormalities in rats and the incidence of skull, brain and spine malformations in rabbits. In rats, there were no adverse effects on embryo-fetal development at a dose of 3 mcg/kg/day corresponding to maternal plasma levels of Taflotan acid that were 343 times the maximum clinical exposure based on C_max. In rabbits, effects were seen at a Taflotan dose of 0.03 mcg/kg/day corresponding to maternal plasma levels of Taflotan acid during organogenesis that were approximately 5 times higher than the clinical exposure based on C_max. At the no-effect dose in rabbits (0.01 mcg/kg/day), maternal plasma levels of Taflotan acid were below the lower level of quantification (20 pg/mL).

In a pre- and postnatal development study in rats, increased mortality of newborns, decreased body weights and delayed pinna unfolding were observed in offsprings. The no observed adverse effect level was at a Taflotan intravenous dose of 0.3 mcg/kg/day which is greater than 3 times the maximum recommended clinical dose based on body surface area comparison.

There are no adequate and well-controlled studies in pregnant woman. Although animal reproduction studies are not always predictive of human response, Taflotan^® should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.

Women of childbearing age/potential should have adequate contraceptive measures in place.

8.3 Nursing Mothers

A study in lactating rats demonstrated that radio-labeled Taflotan and/or its metabolites were excreted in milk. It is not known whether this drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Taflotan^® is administered to a nursing woman.

8.4 Pediatric Use

Use in pediatric patients is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

8.5 Geriatric Use

No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients.

11 DESCRIPTION

Taflotan is a fluorinated analog of prostaglandin F2α. The chemical name for Taflotan is 1-methylethyl (5Z)-7-{(1R, 2R, 3R, 5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-butenyl}-3,5-dihydroxycyclopentyl]-5-heptenoate. The molecular formula of Taflotan is C₂₅H₃₄F₂O₅ and its molecular weight is 452.53.

Its structural formula is:

Taflotan is a colorless to light yellow viscous liquid that is practically insoluble in water.

Taflotan^® (tafluprost ophthalmic solution) 0.0015% is supplied as a sterile solution of Taflotan with a pH range of 5.5 to 6.7 and an Osmolality range of 260 to 300 mOsmo/kg.

Taflotan^® contains Active: Taflotan 0.015 mg/mL; Inactives: glycerol, sodium dihydrogen phosphate dihydrate, disodium edetate, polysorbate 80, hydrochloric acid and/or sodium hydroxide (to adjust pH) and Water for Injection.

Taflotan^® does not contain a preservative.

Structural Formula

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Taflotan acid, a prostaglandin analog is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.

12.3 Pharmacokinetics

Absorption

Following instillation, Taflotan is absorbed through the cornea and is hydrolyzed to the biologically active acid metabolite, Taflotan acid. Following instillation of one drop of the 0.0015% solution once daily into each eye of healthy volunteers, the plasma concentrations of Taflotan acid peaked at a median time of 10 minutes on both Days 1 and 8. The mean plasma C_max of Taflotan acid were 26 pg/mL and 27 pg/mL on Day 1, and Day 8, respectively. The mean plasma AUC estimates of Taflotan acid were 394 pg*min/mL and 432 pg*min/mL on Day 1 and 8, respectively.

Metabolism

Taflotan, an ester prodrug, is hydrolyzed to its biologically active acid metabolite in the eye. The acid metabolite is further metabolized via fatty acid β‑oxidation and phase II conjugation.

Elimination

Mean plasma Taflotan acid concentrations were below the limit of quantification of the bioanalytical assay (10 pg/mL) at 30 minutes following topical ocular administration of Taflotan 0.0015% ophthalmic solution.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Taflotan was not carcinogenic when administered subcutaneously daily for 24 months at doses up to 30 mcg/kg/day in rats and for 18 months at doses up to 100 mcg/kg/day in mice (over 1600 and 1300 times, respectively, the maximum clinical exposure based on plasma AUC).

Taflotan was not mutagenic or clastogenic in a battery of genetic toxicology studies, including an in vitro microbial mutagenesis assay, an in vitro chromosomal aberration assay in Chinese hamster lung cells, and an in vivo mouse micronucleus assay in bone marrow.

In rats, no adverse effects on mating performance or fertility were observed with intravenous dosing of Taflotan at a dose of 100 mcg/kg/day (over 14000 times the maximum clinical exposure based on plasma C_max or over 3600 times based on plasma AUC).

14 CLINICAL STUDIES

In clinical studies up to 24 months in duration, patients with open-angle glaucoma or ocular hypertension and baseline pressure of 23 to 26 mm Hg who were treated with Taflotan^® dosed once daily in the evening demonstrated reductions in intraocular pressure at 3 and 6 months of 6 to 3 mmHg and 5 to 8 mmHg, respectively.

16 HOW SUPPLIED/STORAGE AND HANDLING

Taflotan^® (tafluprost ophthalmic solution) 0.0015% is supplied as a sterile solution in translucent low density polyethylene single-use containers packaged in foil pouches (10 single-use containers per pouch). Each single-use container has 0.3 mL solution corresponding to 0.0045 mg Taflotan.

NDC 17478-609-30; Unit-of-Use Carton of 30.

NDC 17478-609-90; Unit-of-Use Carton of 90.

Storage:

Store refrigerated at 2° to 8°C (36° to 46°F). During shipment Taflotan^® may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 2 days. Mail-order prescriptions received after two days of dispensing date noted in the prescribing label should not be used. Store in the original pouch. After the pouch is opened, the single-use containers may be stored in the opened foil pouch for up to 30 days at room temperature 20° to 25°C (68° to 77°F). Protect from moisture. Write down the date you open the foil pouch in the space provided on the pouch. Discard any unused containers 30 days after first opening the pouch.

17 PATIENT COUNSELING INFORMATION

17.1 Nightly Application

Advise patients to not exceed once daily dosing since more frequent administration may decrease the intraocular pressure lowering effect of Taflotan^®.

17.2 Handling the Single-Use Container

Advise patients that Taflotan^® is a sterile solution that does not contain a preservative. The solution from one individual unit is to be used immediately after opening for administration to one or both eyes. Since sterility cannot be maintained after the individual unit is opened, the remaining contents should be discarded immediately after administration.

17.3 Potential for Pigmentation

Advise patients about the potential for increased brown pigmentation of the iris, which may be permanent. Also inform patients about the possibility of eyelid skin darkening, which may be reversible after discontinuation of Taflotan^®.

17.4 Potential for Eyelash Changes

Inform patients of the possibility of eyelash and vellus hair changes in the treated eye during treatment with Taflotan^®. These changes may result in a disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are usually reversible upon discontinuation of treatment.

17.5 When to Seek Physician Advice

Advise patients that if they develop a new ocular condition, experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician's advice concerning the continued use of Taflotan^®.

17.6 Use with Other Ophthalmic Drugs

If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes between applications.

17.7 Storage Information

Instruct patients on proper storage of cartons, unopened foil pouches, and opened foil pouches . Recommended storage for cartons and unopened foil pouches is to store refrigerated at 2° to 8°C (36° to 46°F). After the pouch is opened, the single-use containers may be stored in the opened foil pouch for up to 30 days at room temperature 20° to 25°C (68° to 77°F). Protect from moisture.

AKORN

Distributed by: Akorn, Inc.

Manufactured for: Oak Pharmaceuticals, Inc.

Made in France

The Taflotan trademark is owned by Merck Sharp & Dohme Corp. and is used under license.

ZO00N Rev. 08/14

PATIENT INFORMATION

Taflotan ^® (zye OP tan)

(tafluprost ophthalmic solution) 0.0015%

Read this Patient Information before you start using Taflotan^® and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.

What is Taflotan ^® ?

Taflotan^® is a prescription sterile eye drop solution. Taflotan^® is used to lower the pressure in the eye (intraocular pressure) in people with open-angle glaucoma or ocular hypertension when their eye pressure is too high. Taflotan^® belongs to a group of medicines called prostaglandin analogs.

Taflotan^® is not for use in children.

What should I tell my doctor before using Taflotan ^® ?

Before you use Taflotan ^® , tell your doctor if you:

• have or have had eye problems including any surgery on your eye or eyes
• are using any other eye medicines
• have any other medical problems
• are pregnant or plan to become pregnant. It is not known if Taflotan^® will harm your unborn baby. You should use an effective method of birth control while you use Taflotan^®. If you become pregnant while using Taflotan^® talk to your doctor right away.
• are breastfeeding or plan to breastfeed. It is not known if Taflotan^® passes into your breast milk. Talk to your doctor about the best way to feed your baby if you use Taflotan^®.

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.

Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

How should I take Taflotan ^® ?

Read the Instructions for Use at the end of this Patient Information leaflet for additional instructions about the right way to use Taflotan^®.

• Use 1 drop of Taflotan ^® in your eye (or eyes) each evening. Talk to your doctor or pharmacist if you are not sure how to use Taflotan^®.
• Your Taflotan^® may not work as well if you use it more than 1 time each evening.
• If you use other medicines in your eye, wait at least 5 minutes between using Taflotan^® and your other eye medicines.
• Use your Taflotan^® right away after opening. Each Taflotan^® single-use container is sterile and is to be used 1 time then thrown away. Do not save any Taflotan^® that may be left over after you use your medicine. Using Taflotan^® that is not sterile may cause other eye problems.

What are the possible side effects of Taflotan ^® ? Taflotan ^® may cause serious side effects including:

• changes in the color of your eye (iris). Your iris may become more brown in color while using Taflotan^®. This color change may not go away when you stop using Taflotan^®. If Taflotan^® is used in 1 eye only, the color of that eye may always be a different color from the color of your other eye.
• darkening of the color of the skin around your eye (eyelid). These skin changes usually go away when you stop using Taflotan^®.
• increasing the length, thickness, color, or number of your eyelashes. These eyelash changes usually go away when you stop using Taflotan^®.
• hair growth on your eyelids. This hair growth usually goes away when you stop using Taflotan^®.

The most common side effects of Taflotan^® include:

• redness, stinging or itching of your eye
• cataract formation
• dry eye
• eye pain
• blurred vision
• headache
• common cold
• cough
• urinary tract infection

Tell your doctor if you have any new eye problems while using Taflotan^® including:

• an eye injury
• an eye infection
• a sudden loss of vision
• eye surgery
• swelling and redness of and around your eye (conjunctivitis)
• problems with your eyelids

Additionally, the following side effects have been reported in general use:

• worsening of asthma
• shortness of breath

Tell your doctor if you have any other side effects that bother you.

These are not all the possible side effects of Taflotan^®. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Taflotan ^® ?

Important information for Mail-Order Patients: Do not use if prescription is not received within two days of dispensing date.

Keep the foil pouches and Taflotan ^® single-use containers dry.

Before opening the foil pouches:

• Store the unopened foil pouches in a refrigerator between 36°F to 46°F (2°C to 8°C).
• Do not open the pouch containing Taflotan^® until you are ready to use the eye drops.

After opening the foil pouch:

• Store the opened foil pouch at room temperature, between 68°F to 77°F (20°C to 25°C), for up to 30 days.
• Throw away all unused Taflotan^® single-use containers in the opened foil pouch after 30 days.
• Keep the Taflotan^® single-use containers in their original foil pouch.
• After opening the foil pouch, refrigeration is not required.

Keep Taflotan ^® and all medicines out of the reach of children.

General information about the safe and effective use of Taflotan ^® .

Do not use Taflotan^® for a condition for which it was not prescribed. Do not give Taflotan^® to other people, even if they have the same symptoms that you have. It may harm them. This Patient Information leaflet summarizes the most important information about Taflotan^®. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about Taflotan^® that is written for health professionals.

What are the ingredients in Taflotan ^® ?

Active ingredients: Taflotan

Inactive ingredients: glycerol, sodium dihydrogen phosphate dihydrate, disodium edetate, and polysorbate 80, hydrochloric acid and/or sodium hydroxide, and water for injection.

Instructions for Use

Read these Instructions for Use before using your Taflotan^® and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or your treatment.

Important:

• Taflotan ^® is for the eye only. Do not swallow Taflotan ^® .
• Taflotan^® single-use containers are packaged in a foil pouch.
• Do not use the Taflotan^® single-use containers if the foil pouch is opened.
• Write down the date you open the foil pouch in the space provided on the pouch.

Every time you use Taflotan ^® :

Step 1.	Wash your hands.
Step 2.	Take the strip of single-use containers from the foil pouch.
Step 3.	Pull off one single-use container from the strip.
Step 4.	Put the remaining strip of single-use containers back in the foil pouch and fold the edge to close the pouch.
Step 5.	Hold the single-use container upright. Make sure that your Taflotan® medicine is in the bottom part of the single-use container. See Figure A.	Figure A
Step 6.	Open the single-use container by twisting off the tab. See Figure B.	Figure B
Step 7.	Tilt your head backwards. If you are unable to tilt your head, lie down.	Figure C
Step 8.	Place the tip of the single-use container close to your eye. Be careful not to touch your eye with the tip of the single-use container. See Figure C.
Step 9.	Pull your lower eyelid downwards and look up.	Figure D
Step 10.	Gently squeeze the container and let 1 drop of Taflotan® fall into the space between your lower eyelid and your eye. If a drop misses your eye, try again. See Figure D.

• If your doctor has told you to use Taflotan^® drops in both eyes, repeat Steps 7 to 10 for your other eye.
• There is enough Taflotan^® in one single-use container for both of your eyes.
• Throw away the opened single-use container with any remaining Taflotan ^® right away.

This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.

Rx only

AKORN

Distributed by: Akorn, Inc.

Manufactured for: Oak Pharmaceuticals, Inc.

Made in France

The Taflotan trademark is owned by Merck Sharp & Dohme Corp. and is used under license.

Revised: 08/2014

Figure A Figure B Figure C Figure D

Principal Display Panel Text for Container Label:

Taflotan^® 0.0015%

(tafluprost) ophthalmic solution

Rx only

Principal Display Panel Text for pouch Label:

NDC 17478-609-01

Taflotan^®

(tafluprost ophthalmic

solution) 0.0015%

For Topical Application in the Eye

Single-use Containers

Preservative-Free, Sterile

Principal Display Panel Text for Carton Label:

NDC 17478-609-90

Taflotan^®

(tafluprost ophthalmic

solution)

0.0015%

For Topical Application in the Eye

REFRIGERATE (2° to 8°C or 36° to 46°F)

Single-use Containers

Preservative-Free, Sterile

Contains:

Active: Taflotan 0.0015%

(4.5 mcg per single-use container).

Inactive ingredients: Glycerol, Sodium Dihydrogen

Phosphate Dihydrate, Disodium Edetate, Polysorbate 80,

Water for Injection, Hydrochloric Acid and/or Sodium

Hydroxide are added to adjust pH.

Rx only

90 Single-use Containers:

9 pouches x 10 single-use containers

(0.3 mL each)

Taflotan pharmaceutical active ingredients containing related brand and generic drugs:

• Tafluprost

Taflotan available forms, composition, doses:

• Solution; Ophthalmic; Tafluprost 15 mcg / ml

Taflotan destination | category:

• Human:
• Antiglaucoma preparations

Taflotan Anatomical Therapeutic Chemical codes:

• S01EE05 - Tafluprost

Taflotan pharmaceutical companies:

• Agencia Lei Va Hong
• Ferron
• Hong Kong Medical Supplies
• Santen Pharmaceutical

References

1. Dailymed."ZIOPTAN (TAFLUPROST) SOLUTION/ DROPS [AKORN, INC.]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
2. Dailymed."TAFLUPROST: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
3. "Tafluprost". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Taflotan?

Depending on the reaction of the Taflotan after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Taflotan not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Taflotan addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

Review

sdrugs.com conducted a study on Taflotan, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Taflotan consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 23 here

The information was verified by Dr. Rachana Salvi, MD Pharmacology